Medical Oncology

ASCO 2023

Questions discussed in this category

What are your top takeaways from ASCO GI 2023?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

8 Answers available

In what situations, if any, would you recommend NALIRIFOX over FOLFIRINOX for first-line treatment of patients with unresectable pancreatic cancer?

Given the recent update from the NAPOLI-3 trial presented at GI ASCO 2023, the two regimens appear to have similar OS.

3 Answers available

How will the PROSPECT trial presented at ASCO 2023 change your current management of early rectal cancer?

Especially as the study was done before the adoption of total neoadjuvant therapy

3 Answers available

When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?

How are you incorporating CONTACT-03 data presented at #ASCO2023 (Pal et al., PMID 37290461) into your practice? Would you consider immunotherapy re-c...

1 Answer available

What are your top takeaways in GI Cancers from ASCO 2023?

6 Answers available

Will you be offering patients urea-based creams or topical diclofenac for hand-foot prophylaxis with capecitabine after the D-TORCH trial results?

D-TORCH compared topical diclofenac to placebo

3 Answers available

What are your top takeaways in GU Cancers from ASCO 2023?

4 Answers available

What are your top takeaways in Thoracic Cancers from ASCO 2023?

5 Answers available

Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?

4 Answers available

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

4 Answers available

What are your top takeaways in Hematologic Malignancies from ASCO 2023?

8 Answers available

What are your top takeaways in Breast Cancer from ASCO 2023?

4 Answers available

Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?

3 Answers available

How do you sequence HER2-therapy in HER2+ biliary tract cancer with the positive results of tucatinib + trastuzumab and zanidatamab in phase 2 studies?

0 Answers available

Based on the VESPER trial data, do you recommend the full 6 cycles or 3-4 cycles of ddMVAC for neoadjuvant muscle invasive bladder cancer treatment?

GETUG-AFU V05 VESPER TrialDid the ASCO 2023 overall survival data change your practice?

1 Answer available

Papers discussed in this category

N. Engl. J. Med.,

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

JAMA network open, 2024 Jan 02

NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.

The New England journal of medicine, 2013-10-31

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

N. Engl. J. Med.,

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Lancet, 2021 Jun 05

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Eur J Cancer, 2018 Aug 24

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

J Clin Oncol, 2019 Sep 26

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial.

Ann Surg, 2023 Jan 20

Locoregional Failure During and After Short-course Radiotherapy followed by Chemotherapy and Surgery Compared to Long-course Chemoradiotherapy and Surgery - A Five-year Follow-up of the RAPIDO Trial.

Ann Oncol, 2022 Oct 25

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

J Clin Oncol, 2023 Jun 04

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).

N Engl J Med, 2023 Jun 04

Preoperative Treatment of Locally Advanced Rectal Cancer.

N. Engl. J. Med., 2004-10-21

Preoperative versus postoperative chemoradiotherapy for rectal cancer.

JAMA oncology, 2018-06-14

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

Lancet Oncol, 2021 Apr 13

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

J Clin Oncol, 2022 Apr 28

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.

Ann Surg, 2020 Mar

Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.

Future Oncol, 2020 Apr 30

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

Lancet, 2021 Jun 24

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Feb 10

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

Lancet Oncol, 2021 Dec 03

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

Lancet, 2021 Jun 04

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

Lancet, 2023 Jun 02

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Oct 27

Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).

Cancer medicine, 2022 Feb 09

Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Apr 20

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).

Clinical genitourinary cancer, 2020 Oct 15

Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.

Journal for immunotherapy of cancer, 2023 Mar

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).

N Engl J Med, 2022 Apr 11

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

N Engl J Med, 2021 Jun 04

Sotorasib for Lung Cancers with p.G12C Mutation.

N Engl J Med, 2023 Jun 28

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Lancet Oncol, 2021 May 04

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Lancet Oncol, 2023 Jun 02

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

Lancet Oncol., 2015 Sep 09

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

J Clin Oncol, 2022 Jan 07

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).

J Am Coll Surg, 2021 Sep 13

Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Leukemia, 2014-03

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

Lancet Oncol, 2021 Nov 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Blood, 2022 Oct 20

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.

N Engl J Med, 2023 Jun 05

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

N Engl J Med, 2023 Mar 27

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

The New England journal of medicine, 2018-11-15

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

Int J Gynecol Cancer, 2021 Sep 07

ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.

J Clin Oncol, 2023 Jan 30

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

Related Topics in Medical Oncology